JP2004512328A5 - - Google Patents

Download PDF

Info

Publication number
JP2004512328A5
JP2004512328A5 JP2002537718A JP2002537718A JP2004512328A5 JP 2004512328 A5 JP2004512328 A5 JP 2004512328A5 JP 2002537718 A JP2002537718 A JP 2002537718A JP 2002537718 A JP2002537718 A JP 2002537718A JP 2004512328 A5 JP2004512328 A5 JP 2004512328A5
Authority
JP
Japan
Prior art keywords
salt
methylpiperazin
ylamino
pyrimidin
ylmethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002537718A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004512328A (ja
JP4386635B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2001/012442 external-priority patent/WO2002034727A2/en
Publication of JP2004512328A publication Critical patent/JP2004512328A/ja
Publication of JP2004512328A5 publication Critical patent/JP2004512328A5/ja
Application granted granted Critical
Publication of JP4386635B2 publication Critical patent/JP4386635B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2002537718A 2000-10-27 2001-10-26 消化管間質腫瘍の処置 Expired - Lifetime JP4386635B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24381000P 2000-10-27 2000-10-27
PCT/EP2001/012442 WO2002034727A2 (en) 2000-10-27 2001-10-26 Treatment of gastrointestinal stromal tumors

Publications (3)

Publication Number Publication Date
JP2004512328A JP2004512328A (ja) 2004-04-22
JP2004512328A5 true JP2004512328A5 (https=) 2009-02-19
JP4386635B2 JP4386635B2 (ja) 2009-12-16

Family

ID=22920224

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002537718A Expired - Lifetime JP4386635B2 (ja) 2000-10-27 2001-10-26 消化管間質腫瘍の処置

Country Status (25)

Country Link
US (1) US6958335B2 (https=)
EP (1) EP1332137B1 (https=)
JP (1) JP4386635B2 (https=)
KR (1) KR100885129B1 (https=)
CN (1) CN1276754C (https=)
AT (1) ATE321556T1 (https=)
AU (2) AU1826202A (https=)
BR (1) BRPI0114870B8 (https=)
CA (1) CA2424470C (https=)
CY (1) CY1105055T1 (https=)
CZ (1) CZ303944B6 (https=)
DE (1) DE60118430T2 (https=)
DK (1) DK1332137T3 (https=)
ES (1) ES2260317T3 (https=)
HU (1) HU229106B1 (https=)
IL (2) IL155029A0 (https=)
MX (1) MXPA03003703A (https=)
NO (1) NO324948B1 (https=)
NZ (1) NZ525254A (https=)
PL (1) PL209733B1 (https=)
PT (1) PT1332137E (https=)
RU (1) RU2301066C2 (https=)
SK (1) SK287335B6 (https=)
WO (1) WO2002034727A2 (https=)
ZA (1) ZA200302155B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
CA2444867C (en) * 2001-05-16 2010-08-17 Novartis Ag Combination comprising n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2pyrimidine-amine and a chemotherapeutic agent
ES2266553T3 (es) * 2001-06-29 2007-03-01 Ab Science Utilizacion de derivados de la n-fenil-2-pirimidina-amina para tratar las enfermedades inflamatorias.
WO2003003006A2 (en) * 2001-06-29 2003-01-09 Ab Science New potent, selective and non toxic c-kit inhibitors
US20040266797A1 (en) * 2001-06-29 2004-12-30 Alain Moussy Use of potent,selective and non toxic c-kit inhibitors for treating tumor angiogensis
ES2274993T3 (es) * 2001-06-29 2007-06-01 Ab Science Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
JP2004537542A (ja) * 2001-06-29 2004-12-16 アブ サイエンス 炎症性腸疾患(ibd)を治療するための、チロシンキナーゼ阻害剤の使用
EP1461032B1 (en) * 2001-09-20 2008-07-16 AB Science Use of c-kit inhibitors for promoting hair growth
EP1427379B1 (en) * 2001-09-20 2008-08-13 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
DE60307237T2 (de) * 2002-02-27 2007-10-18 Ab Science Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten
FR2844452A1 (fr) * 2002-09-18 2004-03-19 Inst Gustave Roussy Igr Utilisation d'inhibiteurs specifiques de tyrosine kinases pour l'immunomodulation
US7144911B2 (en) 2002-12-31 2006-12-05 Deciphera Pharmaceuticals Llc Anti-inflammatory medicaments
US7202257B2 (en) 2003-12-24 2007-04-10 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
US7279576B2 (en) 2002-12-31 2007-10-09 Deciphera Pharmaceuticals, Llc Anti-cancer medicaments
CA2538523A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
WO2007089716A2 (en) * 2006-02-01 2007-08-09 The Regents Of The University Of California Use of aminopyrimidine compounds in the treatment of immune disorders
AU2007296743B2 (en) * 2006-09-11 2012-02-16 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
WO2008033747A2 (en) * 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US20090082361A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched imatinib
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
US8530492B2 (en) 2009-04-17 2013-09-10 Nektar Therapeutics Oligomer-protein tyrosine kinase inhibitor conjugates
WO2012122058A2 (en) 2011-03-04 2012-09-13 Newgen Therapeutics, Inc. Alkyne substituted quinazoline compound and methods of use
WO2012155339A1 (zh) 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
US20160015708A1 (en) 2012-02-21 2016-01-21 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
JP6464084B2 (ja) 2012-07-27 2019-02-06 イズミ テクノロジー,エルエルシー 排出阻害剤およびこれを用いる治療法
EP3782604A1 (en) 2013-07-31 2021-02-24 Windward Pharma, Inc. Aerosol tyrosine kinase inhibitor compounds and uses thereof
WO2019016673A2 (en) 2017-07-20 2019-01-24 Kashiv Pharma Llc STABLE PHARMACEUTICAL COMPOSITION OF ORAL ADMINISTRATION OF IMATINIB
CN118416236A (zh) 2018-01-31 2024-08-02 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
IL276398B2 (en) 2018-01-31 2026-03-01 Deciphera Pharmaceuticals Llc Combination therapy for mastocytosis
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
US12186393B2 (en) 2019-08-02 2025-01-07 Onehealthcompany, Inc. Method of treating transitional cell carcinoma in a canine by administering lapatinib, wherein the carcinoma harbors a BRAF mutation
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
EP4013412B1 (en) 2019-08-12 2026-01-28 Deciphera Pharmaceuticals, LLC Ripretinib for treating gastrointestinal stromal tumors
MX2022008103A (es) 2019-12-30 2022-09-19 Deciphera Pharmaceuticals Llc Formulaciones de inhibidores de la cinasa amorfa y metodos de estas.
EP4084779B1 (en) 2019-12-30 2024-10-09 Deciphera Pharmaceuticals, LLC Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
KR102535840B1 (ko) 2020-07-31 2023-05-23 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물의 위장관기질종양 예방, 개선 또는 치료 용도
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1528449A1 (ru) * 1985-06-05 1989-12-15 Центральный институт усовершенствования врачей Способ релаксации илеоцекального отдела кишечника
TW225528B (https=) * 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP2002523455A (ja) * 1998-08-31 2002-07-30 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された2−インドリノン誘導体

Similar Documents

Publication Publication Date Title
JP2004512328A5 (https=)
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
RU2470642C2 (ru) Аналоги птерина для лечения состояния, чувствительного к вн4
JP2017504611A5 (https=)
RU2325389C2 (ru) Композиция и производные замещенного азаиндолоксоацетапиперазина, обладающие противовирусной активностью
CY1119001T1 (el) Ενωσεις 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτων για ανευ νοηματος καταστολη και τη θεραπεια ασθενειας
JP2015528471A5 (https=)
JP2004525179A5 (https=)
JP2007519649A5 (https=)
JP2008521827A5 (https=)
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
RU2009147456A (ru) Лекарственное средство, содержащее производное карбостирила и донепезил, для лечения болезни альцгеймера
JP2019517587A5 (https=)
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
JP2009532438A5 (https=)
JP2008513510A5 (https=)
JP2019526546A5 (https=)
IL272092B1 (en) 5-((((1r,2s)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine for use in treating behavior alterations
ATE361918T1 (de) 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2- yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden
RU2005133665A (ru) Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств
JP2011524362A5 (https=)
JP2002529497A5 (https=)
AU2003232805A8 (en) Pharmaceutical active substance combination and the use thereof
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia
DE60135390D1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration